Sarepta Therapeutics Stock Forecast
NASDAQ: SRPTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
After hours: 18.28 +0.39%
SRPT analyst consensus
Consensus (24 analysts)
hold
Avg. price target
$21.73+19.33%
- Strong buy 0
- Buy 7
- Hold 12
- Sell 3
- Strong sell 2
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 24 Wall Street analysts covering Sarepta Therapeutics (2026-10-07), 7 rate the stock a buy or strong buy, 12 rate it a hold and 5 rate it a sell or strong sell, for a consensus rating of "hold". The average 12-month price target is $21.73, with a high estimate of $38.00 and a low estimate of $5.00. The average target implies upside of 19.3% from the current price of $18.21.
The spread between the highest and lowest targets is 660.0%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for SRPT.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 7 | 29% |
| Hold | 12 | 50% |
| Sell | 3 | 13% |
| Strong sell | 2 | 8% |
Ratings as of 2026-10-07.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $5.00 | -72.54% |
| Average target | $21.73 | +19.33% |
| High target | $38.00 | +108.68% |